Skip to main content
. 2020 Aug 11;9(19):7244–7252. doi: 10.1002/cam4.3347

FIGURE 7.

FIGURE 7

The mechanism of ZHX2 promoting proteasome inhibitor resistance. When bortezomib inhibits the proteasome, the degradation of ZHX2 is decreased. Accumulated ZHX2 binding to NF‐κB enhancing nuclear translocation of NF‐κB and activation of NF‐κB target genes expression, which can attenuate the antitumor activity of proteasome inhibitor